Replies to post #222787 on NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

Thanks for running that down with the publisher Evaluate. That's quite a difference (2.1% vs 21%).

I also inquired which are the other 2 Phase III DCV trials for which he is eagerly awaiting results.

I also inquired whether he might want to update his report to take into account the "Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference" to include 2018 (blinded) data.
I also highlighted the reference therein regarding the 28.2% 3-year overall survival and the 49.1% 3-year survival for MGMT gene = methylated.